Ofatumumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), DMC (Denmark) and HAS (France), among others, recommended or restricted ofatumumab, while CONITEC (Brazil) did not recommend it.
The file has been open for more than a decade: 15.1 years separate the first record, 9 Aug 2010 at SMC (Scotland), from the most recent, 30 Sep 2025 at ZIN (Netherlands).
PBAC (Australia) changed its position: recommended in 2014, not recommended by 2024.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for ofatumumab, 1 submission was never made and 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 4 of 22 records date from 2023 or later.
7 distinct indication wordings are recorded for ofatumumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 22 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess ofatumumab, on 9 Aug 2010; PHARMAC (New Zealand) did not open a file until 3 Nov 2023 — an unusually long tail of 13.2 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 9 years in total.
Restriction is doing real work here: 6 of 18 decisive outcomes narrowed ofatumumab to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), DMC (Denmark) and SMC (Scotland) among others.
6 of the 12 agencies here assessed ofatumumab more than once, SMC (Scotland) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
ofatumumab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for ofatumumab reads 7 recommended, 6 restricted, 5 not recommended and 2 withdrawn, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 30 Sep 2025 | Advies - niet wijzigen vergoedingsvoorwaarden ofatumumab (Kesimpta®) voor multiple sclerose | not reimbursed | source |
| HAS (France) | 14 May 2025 | Re-assessment following post-listing study results | SMR substantial | source |
| PBAC (Australia) | 2024 | Multiple sclerosis | Not Recommended | source |
| PHARMAC (New Zealand) | 3 Nov 2023 | Relapsing Remitting Multiple Sclerosis (MS) | PTAC advice: Cost Neutral | source |
| CONITEC (Brazil) | 11 Jul 2022 | Tratamento de esclerose múltipla recorrente em primeira linha de terapia modificadora do curso da doença. | not incorporated | source |
17 further decisions for ofatumumab, across 10 agencies, are not shown here. They link to 14 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 22 decisions for ofatumumab from 12 agencies, 2010 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.